Micra AV Leadless Pacemaker: Clinical Updates and Programming Pearls
Leadless pacing has moved from a niche alternative to an established option for selected patients who need ventricular support without a transvenous lead or subcutaneous generator. The Micra AV system extends this approach by using an accelerometer to detect mechanical atrial activity and coordinate ventricular pacing, offering a VDD-like strategy in patients with intact sinus node function.
Its value is greatest when clinical selection, implantation technique, device programming, and follow-up are considered together. AV synchrony is influenced by atrial mechanical signals, posture, activity, intrinsic conduction, and the patient’s rhythm. A technically successful implant can still produce limited physiologic benefit if the device is programmed without attention to these factors.
The evidence base continues to develop through observational studies, comparative analyses, and longer-term device experience. For clinicians working in electrophysiology, understanding the practical boundaries of Micra AV is as important as knowing its advantages.
Where Micra AV Fits In Contemporary Pacing
Micra AV is designed for patients who require ventricular pacing and have a reasonable expectation of sinus rhythm with useful atrial mechanical activity. Typical scenarios include intermittent or persistent high-grade atrioventricular block, selected patients with permanent atrial fibrillation who instead require a ventricular-only system, and individuals in whom a transvenous system presents particular risk.
The leadless format avoids a pocket, transvenous lead, venous obstruction, and some forms of device-related infection. It may be especially attractive in patients with limited venous access, prior device infection, hemodialysis, recurrent pocket complications, or a high likelihood of future vascular access needs. The absence of a lead does not eliminate procedural risk, however. Femoral access, intracardiac manipulation, cardiac perforation, vascular complications, and the complexity of retrieval or device revision remain relevant.
Patient selection should begin with the pacing indication rather than the device itself. A person with chronotropic incompetence, sinus node dysfunction, frequent atrial arrhythmias, or a strong need for atrial pacing may be poorly served by an accelerometer-based VDD system. A transvenous dual-chamber pacemaker may provide more predictable atrial support and more flexible rhythm management.
Clinical Evidence And Patient Selection
Clinical studies have shown that Micra AV can achieve clinically meaningful AV synchrony in carefully selected patients, particularly at rest and during regular sinus rhythm. The device identifies mechanical atrial contractions through an accelerometer signal and adjusts ventricular pacing timing accordingly. This differs from conventional dual-chamber pacing, which senses atrial electrical activity through a dedicated lead.
Mechanical sensing creates important limits. Atrial contraction may be weak during hypotension, atrial tachyarrhythmia, ventricular ectopy, marked sinus tachycardia, or severe atrial mechanical dysfunction. Motion and posture can also affect signal interpretation. Reported synchrony therefore varies according to the definition used, the monitoring method, the patient’s rhythm, and the amount of time spent in different activities.
The risk of pacing-induced ventricular dysfunction should remain part of the decision process. Patients expected to have a high ventricular pacing burden need baseline and follow-up assessment of left ventricular function, especially when other risk factors are present. A broader review of pacing-induced cardiomyopathy can help frame surveillance strategies and the potential consequences of chronic right ventricular pacing.
A leadless pacemaker is also not a defibrillator or a treatment for ventricular tachyarrhythmia. Patients with a meaningful risk of sudden cardiac death require a separate assessment for an ICD or another appropriate strategy. Similarly, patients who may need cardiac resynchronization therapy should generally be evaluated for a system capable of multisite ventricular activation rather than isolated right ventricular leadless pacing.
Implantation And Early Follow-Up
Implantation is performed through a femoral venous approach, with deployment in the right ventricle at a site that provides stable fixation, acceptable thresholds, and suitable sensing. Septal positioning is often favored to reduce the risk associated with apical deployment, although anatomy, operator experience, and device stability all influence the final location.
At least two fixation tines should generally be confirmed, and the pull-and-hold test, electrical measurements, and imaging findings should be interpreted together. A low capture threshold and adequate R-wave amplitude are desirable, but an apparently good electrical result does not replace careful assessment for perforation or pericardial effusion. Symptoms such as chest pain, hypotension, dyspnea, or unexplained tachycardia require prompt evaluation.
Early follow-up should verify capture threshold, sensing, impedance, battery estimate, pacing percentage, and rhythm diagnosis. The clinician should also review whether the patient is actually maintaining sinus rhythm and whether the device is detecting atrial mechanical activity consistently. A nominal setting may be acceptable initially, but programming should be revisited after the patient resumes ordinary activity.
Remote monitoring can support trend detection, although it does not replace clinical review. Changes in threshold, rising pacing burden, recurrent atrial arrhythmia, or a new decline in ventricular function may alter the long-term plan. MRI conditionality should be documented according to the specific device model and institutional protocol rather than assumed from the leadless design alone.
Programming Pearls For AV Synchrony
The central programming task is balancing AV synchrony against reliable ventricular capture. In patients with stable sinus rhythm and a high-grade AV block indication, an AV-synchronous mode may provide useful atrial contribution and improve hemodynamic comfort. The clinician should confirm that the device is sensing mechanical atrial events at an appropriate rate and that ventricular pacing follows them within a suitable interval.
The accelerometer signal includes cardiac and noncardiac movement. Programming therefore requires attention to activity-related sensing, posture, and the patient’s typical daily routine. A patient who appears synchronized while supine in the clinic may have lower synchrony during walking, exercise, or rapid breathing. Device diagnostics and, when needed, surface ECG or ambulatory monitoring can reveal whether ventricular events are consistently linked to atrial activity.
The upper tracking behavior deserves particular attention. If the sinus rate exceeds the device’s effective tracking range, the system may shift toward ventricular pacing that is less closely associated with atrial contraction. In patients with frequent exertional tachycardia, review rate response, upper limits, and the clinical need for AV synchrony during activity rather than relying on a single resting assessment.
| Programming or follow-up issue | What to assess | Practical response |
|---|---|---|
| Low apparent AV synchrony | Rhythm, posture, activity, mechanical atrial signal | Review diagnostics and obtain ECG or ambulatory correlation |
| Frequent atrial tachyarrhythmia | Mode behavior and ventricular rate | Consider whether VDD-like tracking remains appropriate |
| High pacing burden | Baseline and serial LV function | Monitor for ventricular dysfunction and reassess pacing strategy |
| Rising capture threshold | Implant location, leadless fixation, metabolic factors | Repeat measurements and investigate promptly |
| Poor exercise tolerance | Rate behavior and tracking during exertion | Evaluate with activity-based testing and adjust settings selectively |
| Intermittent intrinsic conduction | AV delay and pacing percentage | Avoid unnecessary pacing when safe and clinically appropriate |
AV delay should be individualized. A short interval may improve timing when intrinsic conduction is absent, while a longer interval can allow native conduction in patients with intermittent block. Excessively long delays may cause symptoms, diastolic mitral regurgitation, or inefficient timing. Programming should therefore reflect the patient’s conduction pattern and hemodynamics rather than a universal default.
Rhythm Changes And Long-Term Management
Micra AV performance can change when the patient’s rhythm changes. Persistent atrial fibrillation removes the physiological basis for AV synchrony, while atrial flutter, frequent premature atrial contractions, and atrial tachycardia can produce irregular or misleading mechanical signals. The device may continue to provide ventricular support, but its original AV-synchronous objective may no longer be achievable.
Medication changes can also affect interpretation. Beta-blockers and antiarrhythmic drugs may alter sinus rate, AV conduction, contractility, and exercise response. A lower activity level or new heart failure can modify the accelerometer signal. Follow-up should connect device diagnostics with symptoms, ECG findings, echocardiography, and medication history.
Battery longevity is usually favorable, but estimates evolve with pacing percentage, output, threshold, and programmed parameters. A replacement strategy must be considered well before end of service. Unlike a conventional generator exchange, placing an additional leadless device raises questions about intracardiac space, device interaction, retrieval feasibility, and the patient’s lifetime pacing plan. In selected cases, retrieval may be possible; in others, abandonment and implantation of a new device may be considered after individualized risk assessment.
The need for future defibrillation or resynchronization therapy should be revisited over time. A patient’s indication is not static, and new cardiomyopathy, sustained ventricular arrhythmia, or worsening heart failure can change the appropriate device strategy.
Safety Signals And Unresolved Questions
The absence of a pocket and transvenous lead reduces several conventional complications, but leadless pacing has its own safety profile. Pericardial effusion, vascular injury, device dislodgement, infection, thromboembolic concerns, and elevated pacing thresholds remain clinically important. Procedural risk may be higher in frail patients, those with pulmonary hypertension, abnormal right ventricular anatomy, or prior cardiac surgery.
Long-term evidence continues to clarify how repeated implants, abandoned devices, and lifetime device burden affect the right ventricle. Data on AV synchrony are also heterogeneous because studies use different definitions and monitoring techniques. A reported synchrony percentage should therefore be interpreted alongside symptoms, exercise capacity, blood pressure, echocardiographic findings, and the patient’s underlying rhythm.
Device choice should also account for broader arrhythmia care. A patient receiving a leadless pacemaker may later need an ICD, and the presence of a leadless system can influence procedural planning. For patients at transient risk of ventricular arrhythmia, discussion of wearable cardioverter-defibrillators may be relevant when permanent device decisions are still evolving.
Practical Recommendations For Clinical Practice
- Confirm the pacing indication, expected rhythm pattern, ventricular function, and likelihood of future atrial pacing before selecting Micra AV.
- Use implantation measurements, fixation assessment, imaging, and clinical observation together when judging procedural success.
- Reassess AV synchrony during ordinary activity, not solely during a resting clinic examination.
- Review pacing burden, capture threshold, battery estimate, rhythm history, and left ventricular function at longitudinal follow-up.
- Reconsider the device strategy when atrial fibrillation, cardiomyopathy, ventricular arrhythmia, or a new need for resynchronization develops.
Micra AV can provide a valuable middle path between ventricular-only leadless pacing and a conventional dual-chamber system, but its benefits depend on matching the technology to the patient’s rhythm and long-term needs. Electrophysiology teams should incorporate device diagnostics with ECG, imaging, symptoms, and functional assessment, while remaining attentive to changes that make another pacing or defibrillation strategy more suitable.
Clinicians, researchers, and trainees can follow emerging evidence through the Journal of Arrhythmia’s arrhythmia and device resources, apply these programming principles in structured follow-up, and contribute further data that refine the role of leadless AV-synchronous pacing.